Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Kevin Koch Biography and Net Worth

President, CEO and Director of Edgewise Therapeutics

Kevin Koch, Ph.D., has served as our President, Chief Executive Officer and a member of our board of directors since 2017 and has been in the life science industry for over 30 years with a focus on drug discovery, translational medicine and clinical development. Since 2016, he has also served as a Venture Partner with OrbiMed. Dr. Koch previously served as the Senior Vice President of Drug Discovery, Chemical and Molecular Therapeutics at Biogen where he managed global drug discovery and biomarker development. Dr. Koch was a co-founder of Array BioPharma, serving as President, Chief Scientific Officer and board member from the company’s inception in 1998 to 2013. While there, he built a fully integrated research and development team that oversaw the invention of over 20 clinical development candidates across multiple therapeutic areas, several of which are now marketed medicines. Prior to Array, Dr. Koch held senior positions at Amgen and Pfizer Central Research. Dr. Koch received a B.S. in Chemistry and Biochemistry from State University of New York, Stony Brook, and his Ph.D. in Synthetic Organic Chemistry from University of Rochester.

What is Kevin Koch's net worth?: The estimated net worth of Kevin Koch is at least $464,019.90 as of May 2nd, 2024. Dr. Koch owns 14,478 shares of Edgewise Therapeutics stock worth more than $464,020 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Koch may own. Additionally, Dr. Koch receives an annual salary of $905,520.00 as President, CEO and Director at Edgewise Therapeutics. Learn More about Kevin Koch's net worth.
How old is Kevin Koch?: Dr. Koch is currently 64 years old. There are 7 older executives and no younger executives at Edgewise Therapeutics. Learn More on Kevin Koch's age.
What is Kevin Koch's salary?: As the President, CEO and Director of Edgewise Therapeutics, Inc., Dr. Koch earns $905,520.00 per year. Learn More on Kevin Koch's salary.
How do I contact Kevin Koch?: The corporate mailing address for Dr. Koch and other Edgewise Therapeutics executives is 3415 COLORADO AVE., BOULDER CO, 80303. Edgewise Therapeutics can also be reached via phone at 720-262-7002 and via email at [email protected]. Learn More on Kevin Koch's contact information.
Has Kevin Koch been buying or selling shares of Edgewise Therapeutics?: Kevin Koch has not been actively trading shares of Edgewise Therapeutics in the last ninety days. Most recently, Kevin Koch sold 3,152 shares of the business's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $18.91, for a transaction totalling $59,604.32. Following the completion of the sale, the chief executive officer now directly owns 14,478 shares of the company's stock, valued at $273,778.98. Learn More on Kevin Koch's trading history.
Who are Edgewise Therapeutics' active insiders?: Edgewise Therapeutics' insider roster includes R. Michael Carruthers (CFO), Behrad Derakhshan (Chief Business Officer), Joanne Donovan (CMO), Jonathan Fox (Director), Kevin Koch (President, CEO and Director), John Moore (General Counsel), Jonathan Root (Director), Alan Russell (Insider), and Peter Thompson (Chairman and Co-Founder). Learn More on Edgewise Therapeutics' active insiders.
Are insiders buying or selling shares of Edgewise Therapeutics?: During the last twelve months, Edgewise Therapeutics insiders bought shares 2 times. They purchased a total of 465,402 shares worth more than $5,100,965.10. During the last twelve months, insiders at the sold shares 16 times. They sold a total of 592,545 shares worth more than $11,865,014.27. The most recent insider tranaction occured on September, 23rd when General Counsel John R Moore sold 20,922 shares worth more than $578,074.86. Insiders at Edgewise Therapeutics own 24.1% of the company. Learn More about insider trades at Edgewise Therapeutics.
Information on this page was last updated on 9/23/2024.

Kevin Koch Insider Trading History at Edgewise Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/2/2024	Sell	3,152	$18.91	$59,604.32	14,478
5/2/2023	Sell	3,203	$8.90	$28,506.70	7,213

Kevin Koch Buying and Selling Activity at Edgewise Therapeutics

Edgewise Therapeutics Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Today's Range

Now: $32.05

$31.92

$32.61

50 Day Range

MA: $30.37

$16.86

$36.62

2 Week Range

Now: $32.05

$5.93

$38.12

Volume

3,693 shs

Average Volume

944,139 shs

Market Capitalization

$3.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Kevin Koch Biography and Net Worth

What is Kevin Koch's net worth?

How old is Kevin Koch?

What is Kevin Koch's salary?

How do I contact Kevin Koch?

Has Kevin Koch been buying or selling shares of Edgewise Therapeutics?

Who are Edgewise Therapeutics' active insiders?

Are insiders buying or selling shares of Edgewise Therapeutics?